Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR and OR in Treatment-naïve Marginal Zone Lymphoma
NCT07008053Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in marginal zone lymphoma (MZL), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Complete Response Rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
orelabrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT07008053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07008053.